These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25324142)

  • 21. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
    Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
    Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.
    Cheng L; Ren W; Xie L; Li M; Liu J; Hu J; Liu BR; Qian XP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):1-13. PubMed ID: 24916545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
    Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].
    Bibeau F; Frugier H; Denouel A; Sabourin JC; Boissiere-Michot F
    Bull Cancer; 2009 Dec; 96 Suppl():S15-22. PubMed ID: 20034866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].
    Sipocz I; Kulka J; Pintér T
    Magy Onkol; 2005; 49(4):337-42. PubMed ID: 16518479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.
    Lee KW; Lee SS; Kim SB; Sohn BH; Lee HS; Jang HJ; Park YY; Kopetz S; Kim SS; Oh SC; Lee JS
    Clin Cancer Res; 2015 Jan; 21(2):357-64. PubMed ID: 25388162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.
    Kundu S; Ali MA; Handin N; Padhan N; Larsson J; Karoutsou M; Ban K; Wiśniewski JR; Artursson P; He L; Hellström M; Sjöblom T
    Genome Med; 2018 Jan; 10(1):2. PubMed ID: 29301589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secretome profiling of heterotypic spheroids suggests a role of fibroblasts in HIF-1 pathway modulation and colorectal cancer photodynamic resistance.
    Lamberti MJ; Rettel M; Krijgsveld J; Rivarola VA; Rumie Vittar NB
    Cell Oncol (Dordr); 2019 Apr; 42(2):173-196. PubMed ID: 30756254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
    Takegawa N; Yonesaka K
    Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer.
    Eng C
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):174-5. PubMed ID: 18391915
    [No Abstract]   [Full Text] [Related]  

  • 33. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
    Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
    Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.
    De Angelis ML; Zeuner A; Policicchio E; Russo G; Bruselles A; Signore M; Vitale S; De Luca G; Pilozzi E; Boe A; Stassi G; Ricci-Vitiani L; Amoreo CA; Pagliuca A; Francescangeli F; Tartaglia M; De Maria R; Baiocchi M
    Stem Cells Transl Med; 2016 Apr; 5(4):511-23. PubMed ID: 26956206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies.
    De Angelis ML; Bruselles A; Francescangeli F; Pucilli F; Vitale S; Zeuner A; Tartaglia M; Baiocchi M
    Cell Biol Toxicol; 2018 Dec; 34(6):459-469. PubMed ID: 29478126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular targeted therapy in colorectal cancer and its resistance].
    Shitara K; Muro K
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):557-66. PubMed ID: 19381027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies.
    Bertotti A; Sassi F
    Clin Cancer Res; 2015 Aug; 21(15):3377-83. PubMed ID: 26071484
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
    Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
    Torlot L; Jarzab A; Albert J; Pók-Udvari Á; Stahler A; Holch JW; Gerlinger M; Heinemann V; Klauschen F; Kirchner T; Kumbrink J; Küster B; Jung A
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):669-682. PubMed ID: 36401637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.
    Beekhof R; Bertotti A; Böttger F; Vurchio V; Cottino F; Zanella ER; Migliardi G; Viviani M; Grassi E; Lupo B; Henneman AA; Knol JC; Pham TV; de Goeij-de Haas R; Piersma SR; Labots M; Verheul HMW; Trusolino L; Jimenez CR
    Sci Transl Med; 2023 Aug; 15(709):eabm3687. PubMed ID: 37585503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.